Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In Japan, freeze-dried live attenuated varicella-zoster vaccine is available for adults aged ≥50 years to prevent herpes zoster. However, limited evidence has been accumulated regarding vaccine safety for patients with underlying illnesses, who have been considered as the high-risk group for herpes zoster. METHODS: A prospective cohort study of 1200 healthy adults and 300 patients with underlying illnesses such as malignancy, diabetes mellitus, autoimmune diseases, and renal diseases was conducted. All subjects were vaccinated and then their adverse events (AEs) were followed for 28 days after vaccination. Key safety measures included any AEs, severe AEs (SAEs), and vaccine-related AEs such as injection-site AEs and systemic AEs. The frequencies and 95% confidence intervals of AEs were calculated. RESULTS: During the follow-up period, 2 SAEs (bone fracture and acute cholecystitis) among healthy adults and 1 SAE (disseminated mycobacteriosis) among patients with underlying illnesses were reported, although none of them was diagnosed as vaccine-related. Vaccine-related AEs were reported in 42% of healthy adults and patients with underlying illnesses, and the proportions were similar between the groups. The most frequent AEs were injection-site AEs in both groups (i.e., 41 and 39%), and systemic AEs were observed in 4% of both groups. Only among healthy adults, those with a history of herpes zoster were more likely to report injection-site AEs than those without a history of herpes zoster (53% vs 39%). CONCLUSIONS: The present study confirmed the safety of freeze-dried, live attenuated varicella-zoster vaccine even in patients with underlying illnesses. A history of herpes zoster might be related to development of injection-site AEs in healthy adults. TRIAL REGISTRATION: The study was prospectively registered on Japic-Clinical Trials Information as JapicCTI-163415 on October 31, 2016.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Both community-acquired and nosocomial infections with pneumococcal bacteria may also be higher among persons with DM”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1826]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“who may also be at greater risk of death from these diseases.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [1826]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults
Oxman, M. N., Levin, M. J., Johnson, G. R., Schmader, K. E., Straus, S. E., Gelb, L. D., Arbeit, R. D., Simberkoff, M. S., Gershon, A. A., Davis, L. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051016 · Cited by 2,412
Efficacy, Safety, and Tolerability of Herpes Zoster Vaccine in Persons Aged 50-59 Years
Schmader, K. E., Levin, M. J., Gnann, J. W., McNeil, S. A., Vesikari, T., Betts, R. F., Keay, S., Stek, J. E., Bundick, N. D., Su, S.-C., et al. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir970 · Cited by 430
Levin, M. J., Smith, J. G., Kaufhold, R. M., Barber, D., Hayward, A. R., Chan, C. Y., Chan, I. S. F., Li, D. J. J., Wang, W., Keller, P. M., et al. (2003) · The Journal of Infectious Diseases · doi:10.1086/379048 · Cited by 314
Zhang, J., Xie, F., Delzell, E., Chen, L., Winthrop, K. L., Lewis, J. D., Saag, K. G., Baddley, J. W., & Curtis, J. R. (2012) · JAMA · doi:10.1001/jama.2012.7304 · Cited by 283
Langan, S. M., Smeeth, L., Margolis, D. J., & Thomas, S. L. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001420 · Cited by 203
Toyama, N., Shiraki, K., & and Members of the Society of the Miyazaki Prefecture Dermatologists (2009) · Journal of Medical Virology · doi:10.1002/jmv.21599 · Cited by 176
Hata, A., Kuniyoshi, M., & Ohkusa, Y. (2011) · Infection · doi:10.1007/s15010-011-0162-0 · Cited by 170
Zoster Vaccine: Current Status and Future Prospects
Oxman, M. N. (2010) · Clinical Infectious Diseases · doi:10.1086/653605 · Cited by 133
Safety of herpes zoster vaccine in the shingles prevention study: a randomized trial.
Simberkoff, M. S., Arbeit, R. D., Johnson, G. R., Oxman, M. N., Boardman, K. D., Williams, H., Levin, M. J., Schmader, K. E., Gelb, L. D., Keay, S. K., et al. (2010) · PubMed · doi:10.7326/0003-4819-152-9-201005040-00004 · Cited by 120
Herpes zoster vaccine live: A 10 year review of post-marketing safety experience
Willis, E. D., Woodward, M., Brown, E., Popmihajlov, Z., Saddier, P., Annunziato, P. W., Halsey, N. A., & Gershon, A. A. (2017) · Vaccine · doi:10.1016/j.vaccine.2017.11.013 · Cited by 112
Research works printed but not linked: 1
- Okada S, Kataoka C, Akechi M. An examination of the immunogenicity and safety of BK1303 (freeze-dried live attenuated varicella vaccine) in healthy adults aged 50 years or older: a phase III, single-center, open-label, uncontrolled trial. J Clin Ther Med. 2014;30:963–74 (In Japanese).
Cited by
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Risk factors for herpes zoster: should people with asthma or COPD be vaccinated?
Safonova, E., Yawn, B. P., Welte, T., & Wang, C. (2023) · Respiratory Research · doi:10.1186/s12931-022-02305-1 · Cited by 80
Varicella zoster virus vaccines: an update
Gabutti, G., Bolognesi, N., Sandri, F., Florescu, C., & Stefanati, A. (2019) · ImmunoTargets and Therapy · doi:10.2147/itt.s176383 · Cited by 67
Parikh, R., Widenmaier, R., & Lecrenier, N. (2021) · Expert Review of Vaccines · doi:10.1080/14760584.2021.1956906 · Cited by 56
Silverii, G. A., Clerico, A., Fornengo, R., Gabutti, G., Sordi, V., Peruzzi, O., Tafuri, S., Mannucci, E., & Dicembrini, I. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02127-7 · Cited by 55
Metadata
- Authors
- Ohfuji, S., Ito, K., Inoue, M., Ishibashi, M., Kumashiro, H., Hirota, Y., Kayano, E., & Ota, N.
- Affiliations
- Osaka City University (JP)
- BIKEN Foundation (JP)
- Corresponding author
- Ohfuji, Satoko
- Venue
- BMC Infectious Diseases
- Published
- 2019-01-28
- Volume
- 19
- Issue
- 1
- Pages
- 95-95
- ISSN
- 1471-2334 (ISSN-L)
- PMC
- PMC6350288
- OpenAlex
- W2936138307
- Cited by
- 18
- References
- 22
- Citations by year
- 2025: 5 · 2024: 1 · 2023: 4 · 2022: 1 · 2021: 3 · 2020: 1 · 2019: 3
- FWCI
- 1.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- Locations
- BMC Infectious Diseases (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- The Research Foundation for Microbial Diseases of Osaka University
- Topics
- Health Sciences › Medicine › Infectious Diseases › Herpesvirus Infections and Treatments
- Health Sciences › Medicine › Emergency Medicine › Intramuscular injections and effects
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- varicella-zoster vaccine, live attenuated vaccine, vaccine safety, herpes zoster prevention, underlying disease, adverse events, injection site reactions, systemic adverse events, disseminated mycobacteriosis, healthy adults, older adults
- MeSH terms
- Injection Site Reaction, Aged, Aged, 80 and over, Autoimmune Diseases, Chickenpox, Chronic Disease, Diabetes Mellitus, Female, Herpes Zoster, Humans, Japan, Kidney Diseases, Male, Middle Aged, Neoplasms, Vaccination, Vaccines, Attenuated, Herpesvirus 3, Human, Comorbidity, Herpes Zoster Vaccine, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study. https://app.cochat.ai/papers/10.1186/s12879-019-3719-7
- The paper
- Ohfuji, S., Ito, K., Inoue, M., Ishibashi, M., Kumashiro, H., Hirota, Y., Kayano, E., & Ota, N. (2019). Safety of live attenuated varicella-zoster vaccine in patients with underlying illnesses compared with healthy adults: a prospective cohort study. BMC Infectious Diseases. https://doi.org/10.1186/s12879-019-3719-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
